[go: up one dir, main page]

ME03378B - Protutijela protiv dkk-1 - Google Patents

Protutijela protiv dkk-1

Info

Publication number
ME03378B
ME03378B MEP-2019-98A MEP201998A ME03378B ME 03378 B ME03378 B ME 03378B ME P201998 A MEP201998 A ME P201998A ME 03378 B ME03378 B ME 03378B
Authority
ME
Montenegro
Prior art keywords
antibodies against
against dkk
dkk
antibodies
Prior art date
Application number
MEP-2019-98A
Other languages
German (de)
English (en)
French (fr)
Inventor
Marcio Chedid
Ryan James Darling
Rachelle Jeanette Galvin
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ME03378B publication Critical patent/ME03378B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2019-98A 2009-04-10 2010-04-06 Protutijela protiv dkk-1 ME03378B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
EP15159780.4A EP2930184B1 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies

Publications (1)

Publication Number Publication Date
ME03378B true ME03378B (me) 2020-01-20

Family

ID=42199718

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2019-98A ME03378B (me) 2009-04-10 2010-04-06 Protutijela protiv dkk-1
MEP-2017-212A ME02798B (me) 2009-04-10 2010-04-06 Protutijela protiv dkk-1"

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2017-212A ME02798B (me) 2009-04-10 2010-04-06 Protutijela protiv dkk-1"

Country Status (30)

Country Link
US (1) US8148498B2 (me)
EP (3) EP2417158B9 (me)
JP (1) JP5759977B2 (me)
KR (3) KR20110124364A (me)
CN (1) CN102388065B (me)
AR (1) AR075989A1 (me)
AU (1) AU2010234611B2 (me)
BR (1) BRPI1014157B1 (me)
CA (1) CA2758252C (me)
CY (3) CY1119399T1 (me)
DK (3) DK2417158T4 (me)
EA (1) EA021401B1 (me)
ES (3) ES2728911T3 (me)
HR (3) HRP20171400T1 (me)
HU (3) HUE043904T2 (me)
IL (1) IL214845A (me)
LT (3) LT3514173T (me)
ME (2) ME03378B (me)
MX (1) MX2011010707A (me)
NZ (1) NZ595011A (me)
PL (3) PL2930184T3 (me)
PT (3) PT2417158T (me)
RS (3) RS62214B1 (me)
SG (1) SG175244A1 (me)
SI (3) SI2930184T1 (me)
TR (1) TR201907261T4 (me)
TW (1) TWI546079B (me)
UA (1) UA103916C2 (me)
WO (1) WO2010117980A1 (me)
ZA (1) ZA201107256B (me)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548817C2 (ru) 2009-05-12 2015-04-20 Пфайзер Инк. БЛОКИРУЮЩИЕ АНТИТЕЛА ПРОТИВ Dkk-1 И ИХ ПРИМЕНЕНИЯ
EP2928923B1 (en) 2012-12-10 2020-01-22 Biogen MA Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
CA2981115C (en) 2015-05-18 2022-05-31 Eli Lilly And Company Anti-dkk-1-anti-rankl bispecific antibody compounds
AU2016316768A1 (en) * 2015-08-28 2018-03-29 Alector Llc Anti-Siglec-7 antibodies and methods of use thereof
CN108697791B (zh) 2015-11-03 2022-08-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
MX2019004940A (es) 2016-10-26 2019-09-26 Leap Therapeutics Inc Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP7382970B2 (ja) 2018-06-08 2023-11-17 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
WO2020014413A2 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
CN114423459A (zh) 2019-09-19 2022-04-29 飞跃治疗公司 Dkk-1抑制剂用于治疗癌症的用途
KR20220131223A (ko) * 2019-11-22 2022-09-27 리프 테라퓨틱스 인코포레이티드 Dkk-1 억제제를 사용하여 암을 치료하는 방법
KR102494042B1 (ko) * 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
EP4288098A4 (en) * 2021-02-05 2025-04-02 Omeros Corporation BIOMARKERS FOR ASSESSING THE RISK OF DEVELOPING ACUTE COVID-19 AND POST-ACUTE COVID-19
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
JP2025523801A (ja) 2022-07-12 2025-07-25 リープ セラピューティクス，インコーポレイテッド 併用療法
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1852507B1 (en) 1997-04-16 2011-04-13 Millennium Pharmaceuticals, Inc. Composition comprising an antibody that selectively binds a cysteine-rich secreted protein (CRSP)
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
EP1490386B1 (en) 1998-03-10 2008-08-13 Genentech, Inc. Novel polypeptide and nucleic acids encoding the same
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
JP2005512508A (ja) 2001-05-17 2005-05-12 ゲノム　セラピューティックス　コーポレーション Ｄｋｋ媒介性相互作用を変調する試薬および方法
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
JP2005512557A (ja) 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
MXPA05013115A (es) 2003-06-06 2006-05-25 Wyeth Corp Metodos y materiales para identificar agentes que modulan la remodelacion de hueso y agentes identificados por los mismos.
US7709611B2 (en) * 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CA2677356A1 (en) * 2007-02-08 2008-08-14 Zhiqiang An Antibodies specific for dkk-1
AU2010245833B2 (en) * 2009-05-07 2014-03-27 Novartis Ag Compositions and methods of use for binding molecules to Dickkopf-1 or Dickkopf-4 or both

Also Published As

Publication number Publication date
AR075989A1 (es) 2011-05-11
WO2010117980A1 (en) 2010-10-14
EA201171237A1 (ru) 2012-04-30
EA021401B1 (ru) 2015-06-30
HUE034625T2 (en) 2018-02-28
LT2930184T (lt) 2019-05-10
PL2417158T3 (pl) 2017-12-29
IL214845A0 (en) 2011-11-30
RS58612B1 (sr) 2019-05-31
BRPI1014157A2 (pt) 2020-09-29
ES2644244T3 (es) 2017-11-28
KR101461362B1 (ko) 2014-11-13
HRP20211343T1 (hr) 2021-11-26
KR20140090273A (ko) 2014-07-16
RS56505B1 (sr) 2018-02-28
DK2930184T3 (da) 2019-05-13
EP2930184B1 (en) 2019-03-27
DK3514173T3 (da) 2021-08-02
SG175244A1 (en) 2011-12-29
EP3514173A1 (en) 2019-07-24
CY1124412T1 (el) 2022-07-22
CA2758252A1 (en) 2010-10-14
CY1119399T1 (el) 2018-02-14
MX2011010707A (es) 2012-02-28
SI2417158T1 (sl) 2017-10-30
EP2417158A1 (en) 2012-02-15
LT3514173T (lt) 2021-09-10
LT2417158T (lt) 2017-10-10
PL3514173T3 (pl) 2022-01-17
AU2010234611A1 (en) 2011-10-20
EP2417158B1 (en) 2017-08-02
TWI546079B (zh) 2016-08-21
CY1121637T1 (el) 2020-07-31
ZA201107256B (en) 2013-03-27
EP3514173B8 (en) 2021-08-04
ES2728911T3 (es) 2019-10-29
PL2930184T3 (pl) 2019-10-31
HUE043904T2 (hu) 2019-09-30
HUE055376T2 (hu) 2021-11-29
KR20110124364A (ko) 2011-11-16
TR201907261T4 (tr) 2019-06-21
JP5759977B2 (ja) 2015-08-05
US20100260754A1 (en) 2010-10-14
HRP20190643T1 (hr) 2019-05-31
KR20140033523A (ko) 2014-03-18
IL214845A (en) 2016-06-30
EP3514173B1 (en) 2021-06-23
CA2758252C (en) 2015-02-24
HRP20171400T1 (hr) 2017-11-03
ES2887176T3 (es) 2021-12-22
CN102388065B (zh) 2014-09-03
US8148498B2 (en) 2012-04-03
SI2930184T1 (sl) 2019-06-28
PT3514173T (pt) 2021-08-16
DK2417158T4 (da) 2018-01-29
UA103916C2 (xx) 2013-12-10
PT2930184T (pt) 2019-06-17
EP2417158B9 (en) 2017-12-06
TW201100101A (en) 2011-01-01
RS62214B1 (sr) 2021-09-30
DK2417158T3 (en) 2017-10-16
BRPI1014157B1 (pt) 2022-01-18
PT2417158T (pt) 2017-10-23
ME02798B (me) 2018-01-20
CN102388065A (zh) 2012-03-21
SI3514173T1 (sl) 2021-09-30
AU2010234611B2 (en) 2013-02-07
EP2930184A1 (en) 2015-10-14
NZ595011A (en) 2013-05-31
JP2012523417A (ja) 2012-10-04

Similar Documents

Publication Publication Date Title
ME03378B (me) Protutijela protiv dkk-1
DK2411442T4 (da) Umættet polyesterresin
DE112010002949A5 (de) Kupplungstastpunkte
DK2430035T3 (da) Uracylspipooxetannukleosider
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112009005462T8 (de) Lenkungsssteuervorrichtung
EP2402744A4 (en) CARBURATION DETECTION METHOD
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
EP2426149A4 (en) ANTI-CADHERIN ANTIBODY
EP2409976A4 (en) GLYCINE TRANSPORTER INHIBITOR
DE112010004865T8 (de) Lamellennassreibkupplung
DOP2011000348A (es) Construcciones casb7439
DK2506968T3 (da) Faujasit-zeolit
DE112010003255A5 (de) Fördergutverteiler
BRPI1010159A2 (pt) bistuti
DE602010000025D1 (de) Fahrzeugsitzgurtvorrichtung
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
DE112010002351A5 (de) Klemmorrichtung
EP2392475A4 (en) NECESSARY TO PAINT
EP2424892A4 (en) DC-STAMP ANTIBODY
EP2485753A4 (en) VARIANTS OF THE CHAPERONINE IN POSITION 10